1-3 of 3
Michael Heinsch
Close
Sort by
Journal Articles

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Amelie Boquoi, MD, Aristoteles Giagounidis, Hartmut Goldschmidt, MD, Michael Heinsch, MD, Mathias J Rummel, MD PhD, Nicolaus Kroeger, David Lopez y Niedenhoff, MD, C. Matthias Wilk, MD, Ingrida Savickaite, MD, Elias K Mai, MD, Carlo Aul, MD, Judith Strapatsas, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Rainer Haas, MD, Guido Kobbe, Roland Fenk, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2003.
https://doi.org/10.1182/blood-2018-99-110977
Published: 2018
Journal Articles

Lenalidomide reexposure After Short Interruption In Del(5q) MDS Patients at Relapse of Transfusion Dependence

Robert Marek Radkowski, Sabine Haase, Brigitte Schlegelberger, MD, PhD, Gudrun Goehring, Stefanie Banisch, MD, Michael Heinsch, Carlo Aul, Aristoteles Giagounidis
Journal: Blood
Blood (2010) 116 (21): 2923.
https://doi.org/10.1182/blood.V116.21.2923.2923
Published: 2010
Journal Articles

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy

Georg Russwurm, Michael Heinsch, Robert Radkowski, Rainer Erlemann, Carlo Aul, Sabine Haase, Aristoteles Giagounidis
Journal: Blood
Blood (2010) 116 (14): 2617–2618.
https://doi.org/10.1182/blood-2010-04-279786
Published: 2010